Recent advances in treatment of epilepsy-related sodium channelopathies

Elisa Musto, Elena Gardella, Rikke S. Møller*

*Corresponding author for this work

Research output: Contribution to journalJournal articleResearchpeer-review


Voltage-gated sodium channels (VGSCs) play a crucial role in generation of action potentials. Pathogenic variants in the five human brain expressed VGSC genes, SCN1A, SCN2A, SCN3A, SCN8A and SCN1B have been associated with a spectrum of epilepsy phenotypes and neurodevelopmental disorders. In the last decade, next generation sequencing techniques have revolutionized the way we diagnose these channelopathies, which is paving the way towards precision medicine. Knowing the functional effect (Loss-of-function versus Gain-of-function) of a variant is not only important for understanding the underlying pathophysiology, but it is particularly crucial to orient therapeutic decisions. Here we provide a review of the literature dealing with treatment options in epilepsy-related sodium channelopathies, including the current and emerging medications.

Original languageEnglish
JournalEuropean Journal of Paediatric Neurology
Pages (from-to)123-128
Publication statusPublished - Jan 2020


  • Epilepsy
  • SCN1A
  • SCN1B
  • SCN2A
  • SCN8A


Dive into the research topics of 'Recent advances in treatment of epilepsy-related sodium channelopathies'. Together they form a unique fingerprint.

Cite this